Studies of doxorubicin treated colon cancer cells and lymphoblast cells provided evidence that non-telomeric DNA damage can also activate the p53-Siah1 pathway and result in proteosomal degradation of TRF2 (Fujita et al., 2010). Here, TP53 is linked to colonic neoplasm.